WHAT WE DELIVER
Focused on significant unmet medical needs, leveraging established expertise in rare diseases, dermatology, and CNS disorders
WHAT WE DO
Drug Repurposing
We develop innovative therapeutics by repositioning approved drugs for new indications, utilizing novel formulations or prodrug designs through the US FDA’s 505(b)(2) regulatory pathway: New Indications: AC-203, New Formulations: AC-203 , AC-1101, Prodrugs: Nora520.
New drug in development
0
Partnerships
0
Geography of Clinical Studies
0
WHAT’S NEW
Staying up to date with our latest developments
We keep our stakeholders informed by providing timely updates on our R&D endeavors, clinical trial progress, regulatory milestones, commercial partnerships, financing activities, and corporate actions, etc.
Aug
27
Press Release．2026
TWi Biotechnology Successfully Completes NTD$450 Million Capital Increase as AC-203 Approaches Key Clinical Readout
Aug
21
Events．2026
TWi Biotechnology Brings Global EB Community Together to Discuss Advances in AC-203 and the Future of EB Care
Jul
24
Events．2026
TWi Biotechnology to Host Global Webinar on Clinical Update and Path Forward for AC-203 in Epidermolysis Bullosa
Jun
15
Press Release．2026
TWi Biotechnology Announces Completion of Primary Endpoint Assessment in Global Phase 2/3 Pivotal Trial of AC-203; Q4 Unblinding Countdown Begins as Company Aims to Deliver the World’s First Treatment for EBS
What are you looking for today?
Quick Links
ESG
From environmental protection and social care to transparent governance, we practice responsible management to create shared prosperity for business and society.
Investors
We continue to deliver on expectations through evidence-based results, sustainable development, and transparent governance. We invite you to join us in witnessing our growing impact.
Working at TWiB
Join us at the forefront of drug development, clinical advancement, and global collaboration—and help create impact that truly matters to society.